Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients. High dose chronic and short-term treatment has been associated with ocular toxicity. We present a case of irreversible visual loss that occurred with a single small "challenge" dose of deferoxamine.
Bene
C
C
Retina and Nephrology Service, Christ Hospital, Cincinnati, OH.
Manzler
A
A
Bene
D
D
Kranias
G
G
D000535:Aluminum / Q000378:metabolism; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008269:Macular Edema / Q000139:chemically induced*; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000139:chemically induced*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D012168:Retinal Pigments; D015354:Vision, Low / Q000139:chemically induced
D012168:Retinal Pigments; D000535:Aluminum; D003676:Deferoxamine